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 Introduction: Ventilator Associated Pneumonia (VAP) is the most 
common complication of patient who are receiving mechanical ventilation. 
VAP is associated with increase morbidity and mortality. 
 Objectives: The aim of this study was to identify the prevalence of VAP 
in ICU and secondly to ascertain the risk factors associated with VAP. 
 Patients and Methods: This was an observational study conducted in 
ICU HUSM. Patient admitted into ICU and who were ventilated was reviewed 
for VAP and the risk factor associated with VAP. Total duration was from 
January 2010 to December 2009. 
 Results: A total of 194 patients fulfilled the criteria and was followed up 
till discharge. It was found that the VAP rate per 1000 ventilator days were 
higher than global VAP rates (19.57 days). Significant risk factors associated 
with VAP was, duration of ventilation (OR 1.073), DM (OR 2.182), transfer out 
of ICU (OR 1.402) and continuous sedation (OR 2.978). Primary pathogen 
involved in VAP in HUSM ICU was Acinobacter sp. 
 Conclusion: The prevalence rate of VAP in HUSM was significantly higher 
than global VAP rates. The significant risk factors were duration of ventilation, 
Diabetes Melittus, transfer out of ICU and continuous sedation. 
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ABSTRAK 
Kelaziman Jangkitan Paru-paru akibat ventilasi dalam Unit Rawatan Rapi 
Hospital University Sains Malaysia. 
 
Pengenalan VAP merupakan satu komplikasi yang biasa berlaku kepada 
pesakit yang menerima ventilasi mekanikal. Kajian ini bertujuan untuk mencari 
kadar, akibat dan risiko VAP dalam HUSM. 
Metodologi Ini merupakan satu kajian pemerhatian yang dikendalikan dalam 
ICU HUSM. Pesakit diperhatikan untuk faktor risiko, tempoh penginapan dan 
akibat VAP. Kajian dijalankan dari Januari hingga Disember 2009. 
Keputusan Sejumlah 194 orang pesakit yang bersesuaian kriteria telah diikuti 
sehingga genap lepas dari ICU. Umur purata pesakit ICU ialah 47.53 tahun dan 
purata lamanya tinggal di ICU adalah 10.94 hari. Ia telah didapati yang kadar 
VAP setiap 1000 hari ventilasi adalah lebih tinggi daripada kadar-kadar VAP 
global(19.57 hari). DM meningkatkan risiko untuk menjangkit VAP dengan OR 
2.182. Tambahan pula, factor pemindahan daripada ICU (OR 1.402) dan ubat 
penenang berterusan (OR 2.978) penting secara statistik (p<0.05) sebagai 
punca untuk VAP. Acinobacter sp. merupakan patogen utama  dalam sample 
BAL pesakit VAP. 
Kesimpulan Kadar VAP dalam HUSM telah didapati lebih tinggi daripada 
kadar-kadar global. VAP meningkatkan tempoh penginapan dan dikaitkan 
dengan DM, pemindahan daripada ICU dan ubat penenang berterusan. 
Patogen utama dalam VAP HUSM adalah Acinobacter sp.   
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ABSTRACT 
Prevalence of Ventilator Associated Pneumonia in Intensive Care Unit Hospital 
University Sains Malaysia. 
Introduction VAP is a common complication of patient who are receiving 
mechanical ventilation. This study aims to provide background prevalence, 
consequences and risk factors of VAP in HUSM. 
Methodology This was an observational study conducted in ICU HUSM. 
Patients were reviewed for background and interventional risk factors, length of 
stay and outcome. The study was conducted from January until December 
2009. 
Result A total of 194 patient fulfilled inclusion criteria and was followed up until 
discharge from ICU. Mean age of ICU patient was 47.53 years and mean 
duration of stay was 10.94 days. It was found that the VAP rate per 1000 
ventilator days were higher than global VAP rates (19.57 days). DM poses 
additional risk for developing VAP with OR 2.182. Additionally intervention risk 
factor, transfering out of ICU (OR 1.402) and continuous sedation (OR 2.978) 
were statistically significant (p<0.05) for VAP development. Acinobacter sp. was 
found to be dominant pathogen from BAL of VAP patient. 
Conclusion VAP rates in HUSM was found to be significantly higher than 
global rates. VAP lead to increase length of stay and is associated with DM, 
transfer out of ICU and continuous sedation. The main pathogen involved in 
HUSM VAP was Acinobacter sp. 
Keywords Ventilator Associated Pneumonia, Prevalence, Risk Factor, BAL 
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 Intensive Unit Care is the epitome of acute critical care. Most physicians 
would agree that the best level of care in a hospital should and is available in 
the intensive care unit. The critical problem is ICU has limited resources in 
terms of physical infrastructure such as beds and ventilator, and as well with 
man power. VAP is associated with ICU increase morbidity and mortality. Thus 
eliminating or at least reducing VAP is vital in optimizing ICU resources. 
4.0 Discussion 
 
 This study was conducted to determine the level of VAP in Hospital 
University Sains Malaysia. The aim was to identify possible links and causes of 
VAP. It stands to serve either to protect current ICU management or identify 
potential loop holes. 
 
 Demographic data of the patients shows a deposition for male patient 
(60%) compared to female (40%). Similar demographic proportion of gender 
has been described in both local and international ICUs.  
4.1 Demongraphic Data 
 
 The mean age of the patients were 47.53 years with mode age group of 
60-69 years. This proportion of patients is similar with patient population in 
general hospitals of Malaysia, but differs from those of international ICU which 
have a higher mean age 62.30 years. 
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 Demographical, the data statistically suggest that HUSM ICU patient 
does not differ from that of local hospital but differ from those of foreign hospital 
in terms of population age. This agreement allowed the assumption prevalence 
rate of VAP between HUSM and local hospital would not be due to age and sex. 
Assumption between HUSM and foreign hospital must take into account age 
and sex as potential risk factors. 
 
 The prevalence rate in HUSM was found to be 20% and VAP rate per 
1000 ventilator days stood at 19.57. This rates when compared to local hospital 
VAP rates were significantly similar, NAAICU reported VAP rate per 1000 
ventilator days at 15.4. When compared to foreign hospital (9.4%), HUSM VAP 
rates were significantly higher. 
4.2. VAP prevalence 
 
 VAP rates from a review in 2006 stood at 26.3% (Gopal Katherason et al, 
2006). Despite a reduction of 30% from 26.3% to 20% over the duration of 2 
years, this reduction could have been more drastic.  
 
 Targeted reduction policy on VAP rates in ICU has been shown to be 
able to reduce VAP rates by 50% and in some centers able to achieve 0% VAP 
(Winkley et al 2010). Targeted reduction or goal directed intervention comprise 
of dedicated regimental implementation of VAP bundle, regular professional 
reminder and education, daily VAP monitoring and goal re-evaluation. Currently 
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HUSM does not have a targeted reduction policy. VAP bundles are not strictly 
implemented, professional education does not always translate to practice, and 
VAP monitoring is done periodically. Partial VAP bundle implantation may have 
contributed to the rate of 20% compared to VAP rate prior to VAP bundle 
practice 60%.  
 
 VAP patient in HUSM also has an increase in ICU stay, mean duration of 
21.2 days compared to non-VAP patient with 13.7 days. This increase length of 
stay of 8 days is echoed in other VAP studies. 
 
 The length of hospital stay was not followed up in this study. Although it 
can be assumed that the length of hospital stay also could increase. Further 
follow up in this patient population can be done to identify if there was 
statistically significant increase length of stay. 
 
 The expected cost of care can be calculated during the ICU stay 
 Patient X increase duration X cost expected per day VAP= expected cost 
38 X 8.3 X RM15000-RM40000 = RM 2,166,000 to RM 12,616,000 
This additional cost of care for VAP patient increased the cost of HUSM ICU by 
RM2mil- RM12mil. This cost includes cost of treatment, equipment and 
manpower.  
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 In terms of bed and ventilator, 256 days of ventilator days were lost. 
Approximately a ventilator day was lost per every day of the year, which means 
another patient could have benefited from ICU admission and support. 
 
 Outcome of patient with VAP was a mortality rate of 36.8% and non-VAP 
patient 31.4%. Significant testing showed odds ratio 0.785 and p-value 0.525, 
which means VAP did not increase the mortality rate of patient in HUSM ICU.  
In contrast VAP classically has been attributed with increased mortality rate of 
over 20%. Recent studies done in the United States of America showed 
contrast result in terms of mortality. Studies done in a community hospital 
showed a significant increase 45.7% p= 0.004 (Emad H. Ibrahim et al, 2001) 
but a large database showed no increase, mortality 30.5% p=0.713 (Jordi Rello 
et al, 2002). 
 
 Several explanations can attribute to this. First HUSM ICU does not 
enforce stringent ICU admission criteria. Thus patient admitted could possible 
initially have a high morbidity and mortality. This would lead to mortality dilution 
of the results causing the result of no difference in mortality rate. Future 
investigation can resolve this issue by risk stratification of patient using 
APACHE III or SAP II and readjusting the mortality rate. 
 
 Another issue is the usage of antibiotics. If the general ICU pathogen 
strain and sensivity involved in VAP is known, and targeted antibiotic sensivity 
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treatment is initiated early, the mortality of VAP could have been reduced. 
Current antibiotic regime in sepsis management in HUSM is cause-targeted 
initially followed by de-escalation. Treatment of suspected VAP is currently is 
from either carbapenem, beta lactamase group or polymyxin depending on the 
onset of VAP. As pathogen involved in VAP in HUSM is primary Acinobacter sp. 
susceptible to polymyxin, current practice might had lead to reduce mortality. 
 
 Despite the lack of evidence between VAP and mortality, prevention of 
VAP should still take precedence. Other issue proven statistically as increase 
ICU stay provide significant reason to act more aggressively. The economical 
and clinical importance cannot be underestimated as prevention is possible. 
Aggressive VAP bundle implementation with future prevalence screening would 
show if VAP rate is reduce. Price-tagging treatment management might also 
increase awareness of cost effective prevention rather than cost effective 
treatment. This would help the finance department to assist in prevention rather 
than withholding high cost treatment especially antibiotics during times of 
budget constraint. 
 
Risk factors were analysed within three components, demographic risk, 
background risk and intervention risk factors. Initial Odd Ratio were analysed 
using simple logistic regression and significant risk factors were reanalysed 
using multiple logistic regression to attained Adjusted Odd Ratio due to 
interaction between risk factors. 
4.3 Risk Factors 
61 
 
 
 Factors which were analysed were age of the patient, sex of the patient 
and the duration of ICU stay. Age and sex showed no significant risk towards 
VAP. On the other hand, duration of ventilation showed an increase risk for VAP 
(OR 1.072). This in term signify a 7% risk of developing VAP per day of 
ventilation. 
4.3.1. Demographic Risk Factor 
 
 Studies such as Emad et al (2001) and Kollef (1993) produced similar 
results in non significant Odd Ratio for sex and age towards VAP. Result from 
Jordi Rello et al (2002) in the other hand showed significant risk associated with 
male population and elderly patient. Multiple other studies also showed similar 
contrast in result and general consensus is age and sex may pose increase risk 
when other risk factors are present. 
 
 Duration of ventilation has been repeatedly shown as a risk factor for 
VAP. Donald E Craven (2006) showed a risk ratio of 3% per day. Marin H. 
Kollef (1993) showed an Odds ratio of 3.65 (p<0.001) when patient was 
ventilated more than 5 days. 
 
 In other words duration of ventilation is a significant risk for developing 
VAP individually. Logically, attempts to reduce the need of ventilation will result 
in the reduction of VAP. Balance between early extubation and risk of failed 
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weaning or extubation have been evaluated (MacIntyre et al, 2001). A weaning 
protocol helps in the decision of weaning and reduces risk of reintubation. 
Weaning protocols consist of weaning index and step down weaning procedure. 
Weaning protocols are not fool-proof, but are especially useful in streamlining 
process of extubation. Presence of a weaning protocol, also ensure junior 
medical staff are aware of the need of weaning early and alert them of red flags 
of possible failure. The benefit of weaning protocol has been proven to reduce 
ventilator duration with no increase risk of complication. Implementation of 
weaning protocol thus would reduce ventilation duration and subsequently 
reduce risk of patient developing VAP. 
 
 In this study of background risks several setbacks were met. Two risk 
factors could not be statistically analysed due to complete one sided data. The 
two data were burn and immunocompromised patients. No burn patients fit the 
inclusion criteria during the period of the study. This was partial due to the fact 
that burn patient were initially ventilated in separate burn unit unless occupancy 
was full in the burn unit. A small number of patients were found to be 
immunocompromised during the study. 
4.3.2 Background Risk Factors 
 
 Simple logistic regression revealed Diabetis Mellitus (DM) as a significant 
risk factor. DM had a risk factor of 200% or doubled the odds ratio for 
developing VAP compared to a non-DM patient. Multilogistic study continued to 
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show that DM remained a risk for VAP. Result from several other studies also 
supported this relation between VAP and DM. 
 
 Diabetes mellitus is attributed to several reduction in host defence 
mechanisms. DM is known to reduce mucociliary motility, increase risk of reflux, 
increase gastric sphincter weakness, reduce gastric motility, decrease white 
blood cell activity, poor wound healing and reduce local microperfusion. DM 
thus not only increased risk of colonization but also reduces the host response 
towards infection. 
 
 Compared to the other background factors, DM risk towards VAP may be 
due to this combined activity of increase colonization and reduce defence 
mechanism. Other risk factors either caused reduce host defence or increase 
risk of colonization. Taken this into account, diabetic patients have a high 
susceptibility to develop VAP in ICU ventilation setting. Patient with diabetes 
which are ventilated should have a lower threshold to be diagnosed and treated 
as VAP. 
 
 Intervention risk factors were documented as patient care progressed. 
Statistic analysis of the 7 risk factor initially showed only 1 significant risk factor. 
Subsequent multilogistic regression adjustment showed 2 significant risk 
factors. 
4.3.3 Intervention Risk Factors 
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 Transfer out of ICU either for diagnostic or therapeutic intervention was 
statistically significant with Odd ratio of 1.403 or 40% increase risk. Transferring 
of patient is technically and physically stressful for the patient and health care 
provider. It requires movement of patient which could cause dislodgement of 
organism into the ETT in terms of aspiration and also biofilm separation. 
Vigorous ambubagging may cause barotraumas, ETT migration and induction 
of organism into the airway. Another cause would be breathing circuit left 
exposed in the ICU during the absence of the patient. This is a potential source 
of entrance for bacteria as the circuit end is no longer attached to the patient. 
Subsequently the bacteria will be transferred to the patient when ventilation 
resumes. Whereas in circuit change, which showed no significant risk for VAP, 
as the circuit is replace with new tubing which are  sterile. 
 
 Continuous sedation was also found to be statistically significant with p= 
0.034, OR 2.978. This is congruent with other study. The cause of this increase 
risk is due to the relation between sedation and prolonged ventilation. In the 
presence of continuous sedation, the duration of ventilation is increased to 140 
hours compared with intermittent sedation of 70 hours. Marin H. Kollef et al 
(1993) showed an increase of 70 hours and John P. Kress et al (2002) showed 
58 hours. This significant increase in ventilation days correlates with the 
increase risk of VAP and duration of ventilation. 
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 Currently the management in HUSM ICU has embarked on sedation 
holiday rather than the traditional continuous sedation. Sedation holiday aims to 
withhold sedation for a time period everyday to a level acceptable for the patient 
condition. Sedation holiday is important as prolonged effect of sedation which 
include lethargy, muscle weakness, loss of cohesiveness and disorientation all 
lead to slower extubation. Protocol driven sedation holiday have been shown to 
be effective and does not increase risk of unplanned extubation. Current 
management should continue with sedation holiday as the benefits are 
statistically significant. Improvement such as a protocol for sedation and 
sedation holiday should be implemented to reap this benefit.  
 
 Other factors such as circuit change and prior antibiotics were not 
statistically significantly. Literature on both these factor are divided, with some 
being a risk reduction while others being risk additive. Further evaluations on 
these factors are not forthcoming as practice of circuit change has evolved from 
change when soiled rather than routine time based change. Data for additional 
risk where traditionally based on time based change. Circuit change when 
soiled has been proven to be safe and does not lead to contamination of circuit 
by new organism for infection.  In this study no routine circuit change was done, 
and only soiled circuit were replace. As there is no significant statistic, this 
practice cannot be validated. 
 
 Antibiotic usage has been implicated in increase risk of VAP by inducing 
more high risk bacteria. This however account for late onset VAP, proper 
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antibiotic usage should reduce early onset VAP. As the practice of prior 
antibiotic is primary the discretion of referring department to ICU, advisory on 
usage cannot be controlled. Divided result on benefit and risk due to VAP also 
lead to poor support against this practice. Additionally withholding antibiotic 
solely to prevent VAP is not advisable as risk of mortality from delayed antibiotic 
administration for sepsis is significant 10% every hour of delay. 
 
 Nasogastric(NG) tube insertion has been associated with VAP in several 
studies. NG tube is suspected to cause sinus infection which is a possible 
source of VAP. Also the NG in several studies have been shown to increase 
risk of aspiration. On the other hand NG tube have benefits such as the ability 
to decompressed the stomach, early feeding, and increase gut motility, which 
are protective against VAP. Thus in this study, both risk and protective effect of 
NG tube negated each other. Current practice in HUSM  ICU is for early 
insertion of NG tube followed by feeding. Since this does not statistically 
increase risk of VAP the practice should proceed for other benefits of early 
feeding. 
 
 Usage of paralytic agents was found not significant as a risk factor, but 
OR showed a protection against VAP. Although p value was > 0.005 it was less 
than 0.01, thus may still be significant clinically. This is incongruent with other 
findings which suggest paralytic agents as risk for VAP. Specific for this study 
80% of the patient that were on paralysis agent were found to be under plastic 
reconstructive surgery patient that were paralysed to preserved free flap post 
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operatively. Paralysis was continued for 24-48 hours and taper off after that 
duration. This short duration of paralysis probably did not increase risk of VAP. 
In fact most patient from this subset did not develop VAP. The possible 
explanation for this observed protective factor, maybe due to the intensive 
hourly monitoring post operatively to ensure flap viability and not due to 
paralysis agent per se. This close care and management probably translated to 
better care and strict adhere to hand washing protocol. Most of this patient from 
this subset was primary ASA 1-2 preoperative. This suggested a healthier group 
of a patient compared to general admission which composed of sepsis or 
trauma patient. 
 
 A total of 38 VAP patients were identified during the study, of which 25 
BAL sample was obtained. This was a 65.7% of the VAP patients. Pathogen 
yield from the BAL showed a predominance of Acinobacter sp. Acinobacter sp. 
has been implicated as a late onset VAP causative organism. Research by 
Donald E. Kraven et al reviewed the pathogen involved with VAP which is 
divided into early onset VAP which were likely community acquired and 
responsive to treatment, and late onset VAP which organism were hospital 
acquired with resistant pattern and subsequently harder to treat. This late onset 
VAP were labelled as high risk infection due to the increase mortality and 
morbidity. 
4.4 BAL sampling 
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 The result of 70% of total BAL sample showed Acinobacter sp. which 
were multiresistant. Multiresistant Acinobacter sp. are most likely Acinobacter 
Baumannii. This primary organism has been implicated clinically in HUSM ICU 
as cause of several outbreak. 
 
 When compared to other local data, this pattern is different as the local 
ministry of health VAP organism was basically Klebseilla sp.  This difference is 
crucial as early targeted antibiotics should cover Acinobacter, rather than 
Klebseilla. Transferred health care practitioner to HUSM ICU must be made 
aware of this, so that proper antibiotic will be initiated during suspected VAP 
cases. 
 
 BAL sampling does not increase specificity nor sensivity during the 
diagnosis of VAP, but is important during targeted treatment. BAL sample 
provided actually organism involved in VAP and helps in de-escalation of 
antibiotics. Thus from this study, management of HUSM ICU should cover late 
onset VAP suspected patient with an anti-Acinobacter antibiotic such as 
Polymyxin and Sulperazone. This is in line with current practice, and therefore 
should be continued. The possible benefit for further investigation is the 
correlation between BAL sampling and trachea aspirate sampling to provide 
early organism diagnosis. This would then reserved BAL sampling for second 
pathogen isolation when early antibiotic targeted trachea aspirate fail to show 
signs of improvement. 
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Several limitations were present in this stud 
5.0 Limitation 
1. Criteria of VAP were solely on CDC NNIS criteria which were acceptable 
but not a Gold standard criteria. 
 
2. Clinical diagnosis was done by solely by the researcher and may be bias. 
 
 
3. Patients were not risk stratified during admission for correlation of 
mortality and morbidity. 
 
4. Two background risk factors failed to provide adequate sample for 
statistic calculation. 
 
5. BAL sample was limited towards stable VAP patient. 
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A few recommendations for future management of VAP: 
6.0 Recommendation 
1. Survey of VAP should be made a key index performance benchmark. 
 
2. VAP bundle protocol should be implemented stringently. 
 
3. Diabetic patient should have a low index for VAP. 
 
4. Sedation protocol should be implemented strictly. 
 
5. Weaning patient from mechanical ventilation as soon as possible. 
 
6. Transport facilities and care during transportation should be emphasized.  
 
7. Current practice of nasogastric tube for feeding should be continued. 
 
8. Current practice of circuit change when soiled should be continued. 
 
9. Current practice of antibiotic coverage of Acinobacter should be 
continued. 
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This study was able to fulfil the objective set forth at the start. We were able to 
answer the question outlined by the study. 
7.0 Summary and Conclusion 
 
The study was able to determine the VAP prevalence of ICU HUSM was 19.57 
per 1000 ventilator days. This was significantly higher than global current VAP 
rates but was similar with local prevalence. 
 
Risk Factor attributed to VAP was identified, duration of ventilation (OR 1.073), 
Diabettes Melittus (OR 2.182), transfer out of ICU (OR 1.402) and continuous 
sedation (OR 2.978). 
 
Primary pathogen involved in VAP in HUSM ICU was Acinobacter sp. 
1 
 
1.0 INTRODUCTION AND LITERATURE REVIEW 
 “Inflammation of the lung parenchyma due to infection causes which is 
not present or incubating at the time of initiation of mechanical ventilator support 
and develops >48 hours after the initiation of the support” VAP as defined by 
ATS/IDSA. 
1.1 Ventilator Associated Pneumonia (VAP) 
 
 Ventilator Associated Pneumonia (VAP) is one of the most common 
infection to occur in Intensive Care Unit (ICU) (Nasia Safdar et al, 2005). Up to 
27% of patient in ICU are documented to acquire VAP. Prevalence rate of VAP 
in United States of America range from 9.3% to 15.0 %, Europe 8.0% to 28.0 %, 
and Asia 2.0 to 40.0%. Malaysia VAP rate range from 5.7% to 51.7% have been 
documented. This represents a common picture of VAP occurrence globally. 
Traditionally VAP rates were documented as percentage of VAP per ventilated 
patients. Recently it has been proposed that VAP rates to be documented as 
VAP per 1000 ventilated days. This change was supposedly due to better 
accurate presentation of VAP. Currently VAP rates are still being reported in 
both methods and remain in transitional period. 
 
 VAP is also the highest mortality associated infection with rates up 90% 
mortality in some centers. This mortality rate has somewhat reduce to 50% in 
recent times due to better understanding and awareness of ventilator bundle for 
ventilated patient. VAP increases the length of ICU and hospital stay from 4 to 
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14 days. The length of ventilated days are purposely increased by 8 days. This 
increase length of stay and also associated additional care to ventilated patient 
is estimated to increase the cost of health care by RM 15 000 to RM 60 000 per 
patient (Steven M. Koenig et al, 2006). More than cost, VAP depletes the limited 
resources within an ICU especially beds and ventilators. This is especially 
important in Malaysia where ICU beds are scarce and outside ICU critical care 
is severely limited. Shortage of ICU beds has been a national concern, requiring 
proactive management from the Ministry of Health by close documentation of 
ICU availability and pooling of regional ICU beds for better efficiency. The 
ministry does acknowledge the importance of VAP and has been closely 
monitoring VAP rates within all ministry hospitals. 
 
 VAP although commonly coined by most doctors, remains a challenge in 
prevention, diagnosis and treatment of the disease. Multiple guidelines have 
been drawn up by several major healthcare groups such as Centre for Disease 
Control and Prevention (CDC) which includes VAP bundle care for prevention. 
Malaysia’s Ministry of Health, National Committee on National Audit on Adult 
ICU (NAICU) initiated since 2003 has strategically and persistently included 
VAP as part of the audit. NAICU both advise and gather audits from local ICU 
and produce a yearly report and recommendation. NAICU also advice and 
outline VAP bundle for local hospitals. Currently, the VAP bundle is neither 
encompassing nor enforced as it is an advisory. 
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 To date the diagnosis of VAP remain a challenge mainly because there 
is no gold standard for the diagnosis of VAP. As of such, several criteria for 
diagnosis of VAP have emerged over the years. To diagnosis of VAP, several 
approaches have been suggested. Among those advocated are:- 
a) Clinical Judgement 
b) Pathology analysis 
c) Biomarkers 
 
 VAP was initially a diagnosis of clinical judgment, pioneered by Johanson 
et al in 1972. He combined both radiology findings and clinical features to 
support his diagnosis of VAP.  
 
Johanson Criteria  
a) Presence of a new or progressive radiographic infiltrate. 
b) Plus at least two or three clinical features: 
• Fever >38°C 
• Leukocytosis or leucopenia 
• Purulent secretions 
 
 This criteria for VAP, although established in 1972, became the 
reference for future VAP diagnosis. Later criteria continued the pattern 
combining both radiograph and clinical judgment in the diagnosis of VAP. Two 
other criteria are currently in use, Clinical Pulmonary Infection Score (CPIS) and 
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Centre for Disease Control and Prevention National Nosocomial Infection 
Surveillance (NNIS).  
 
Clinical Pulmonary Infection Score (CPIS) 
• Temperature 
0 point : 35.5-38.4°C 
1 point : 38.5-38.9°C 
2 point : <36 or >39°C 
• Blood leukocyctes (cells/µL) 
0 point : 4000-11000 
1 point : <4000 or >11000 
2 point : >500 band forms 
• Oxygenation (PaO2/FiO2) 
0 point : PaO2/FiO2 > 240 or ARDS 
2 point : PaO2/FiO2 < 240 and no evidence of ARDS 
• Pulmonary radiography 
0 point : no infiltrate 
1 point : diffuse or patchy infiltrates 
2 point : localized infiltrare 
• Tracheal secretions (score) 
0 point : <14 
1 point : >14 
2 point : purulent sputum 
• Culture of tracheal aspirate 
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0 point : minimal or no growth 
1 point : moderate or more growth 
2 point: moderate or greater growth 
 
NNIS criteria 
• Radiology 
Two or more serial chest radiograph with at least 1 change:- 
o New or progressive and persistent infiltrate 
o Consolidation 
o Cavitation 
• Clnical 
At least 1 of the following 
• Fever (>38°C) with no other recognized cause 
• Leukopenia (<4000WBC/mm3) or leukocytosis (≥12,000 
WBC/mm3) 
• For adults ≥70 years old, altered mental status with no 
other recognized cause 
At least 2 of the following 
• New onset of purulent sputum, or change in character of 
sputum, or increased respiratory secretions, or increased 
suctioning requirements 
• New onset or worsening cough or dyspnea or tachypnea 
• Rales or bronchial breath sounds 
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• Worsening gas exchange (e.g. O2 desaturations [eg 
PaO2/FiO2 ≤ 240], increased oxygen requirements or 
increased ventilation demand) 
 This three criteria scoring for VAP each has been reviewed and tested 
for both sensivity and specificity. Sensivity is important as it provides the pickup 
rate of the disease, and specificity provides the true positive. Achieving both 
high rates for sensivity and specificity have been difficult, often one or the other 
have been traded for improvement of the latter. Plus criteria set have to be 
easily reproduced and generally commonly investigated.  
 
Table 1.1: Sensivity and specificity of VAP diagnosis criteria (Alvaro et al 
2008). 
 Sensivity 
(%) 
Specificity 
(%) 
Johanson 69 75 
CPIS (varies) 72 85 
CDC NNIS 84 69 
 
 Johanson criteria has the lowest pickup rate, thus potentially risking 31% 
patient being undetected and untreated. Both sensivitiy and specificity for CPIS 
is not consistent in literature review This is due to different cut off point of CPIS 
as VAP, certain researches using 5, others 6, leading to sensivity of 30 to 83% 
and specificity of 17% to 80%. CDC NNIS criteria remain consistent with the 
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most patient in the studies, with a pickup rate of 84% but less specific at only 
69%. This leaves less patient being under diagnose but at risk for increase over 
treatment. Although CDC NNIS criteria has not become a global benchmark 
reference for VAP, most researches adopt CDC NNIS criteria in VAP diagnosis. 
CDC NNIS thus is fast becoming a platform for comparison and exchange of 
information on VAP despite fallibility of a lower specifity. 
 
 Other approaches to VAP diagnosis which is pathology analysis relies on 
quantitative cultures obtained from different methods. Methods employed 
include specimens from trachea aspirate and specimens from bronchoscopy 
using both blind and direct visual sampling. Compared to clinical diagnosis, 
pathology analysis does not increase the accuracy of diagnosis. The advantage 
provided by pathology analysis is the presence of positive growth and 
identification of the causative organism. This then provides the target for 
specific antibiotics. 
 
 Biomarkers as tools of diagnosis in VAP are still in their infancies. 
Certain biomarkers already found to be of limited use are endotoxin 
concentration and elastin fibers. While others, are promising but yet to be fully 
research such as C-reactive protein, procalcitonin and soluble triggering 
receptor expressed on myeloid cells (sTREM)-1. 
 
